Weight Loss

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.

A time-restricted eating window of less than 8 hours was associated with increased risk for cardiovascular death, according to study findings presented at the Epidemiology, Prevention, Lifestyle & Cardiometabolic Scientific Sessions.

Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with semaglutide, according to cohort study results published in Menopause.

GLP-1 receptor agonists come with known adverse events — some common and some rare — but recent reports by the public of alopecia and suicidal ideation have the FDA investigating.

The FDA issued a warning to people with diabetes not to use smartwatches or smart rings that do not pierce the skin for measuring blood glucose because the readings could be inaccurate.

Adults with obesity who received an injectable GIP receptor antagonist/GLP-1 receptor agonist every 4 weeks had a decrease in body weight that was maintained for up to 150 days, according to study findings published in Nature Metabolism.

Maintaining high levels of physical activity and weight loss were associated with reduced risks for several cardiovascular events, a study published in JAMA Network Open showed.

SAN FRANCISCO — Severe or morbidly obese patients had increased operative times, estimated blood loss and rates of surgical site infection after lumbar spinal fusion vs. patients with lower BMI, according to data presented here.

The dual incretin agonist tirzepatide reduced 24-hour ambulatory BP for adults with obesity-related hypertension, with the effects potentially independent of weight loss, according to data from a planned substudy of the SURMOUNT-1 trial.

Over half of patients who stopped taking liraglutide or semaglutide were able to maintain their weight for a year, according to a recent study from Epic Research.